AdvanSix Reports Third-Quarter Sales of $430.81 Million, Loss Widens
AdvanSix reported third-quarter 2026 sales of $430.81 million, up 15% year over year. Net loss widened to $7.56 million, with diluted loss per share of $0.28.
AdvanSix reported third-quarter 2026 sales of $430.81 million, up 15% year over year, while net loss widened to $7.56 million and diluted loss per share was $0.28. Higher raw-material pass-through and market pricing drove sales growth, partly offset by lower caprolactam volume.Financial Highlights¹…